Summary

Global Neoantigen Cancer Vaccine Market is expected to grow at a significant rate of around 25% during the forecast period. Neoantigen cancer vaccine is an emerging immunotherapeutic approach that utilizes cancer specific antigens (neoantigens) to induce tumor-specific T cells in patients without killing normal cells, thereby achieving personalized precision treatment. The market is growing at a tremendous rate owing to the increase in the incidences of cancers, the rise in the adoption of personalized medicine to tailor patient treatment on an individual level, and huge funding for conducting research and development activities. For instance, in January 2023, Greenlight Bioscience entered into collaboration with EpiVax Therapeutics to jointly develop and commercialize personalized mRNA-based vaccine candidates for cancers.

F. Hoffmann-La Roche Ltd; AstraZeneca; Merck & Co., Inc.; Gritstone bio; ose-immuno; BioNTech SE; Agenus Inc.; Gilead Sciences, Inc.; BrightPath Biotherapeutics Co., Ltd; and Innovent are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst product, off-the shelf neoantigen vaccine category to hold a dominant share in the market in 2021”
Based on the product, the market is bifurcated into personalized neoantigen vaccine and off-the shelf neoantigen vaccine. Among these, off-the shelf neoantigen vaccine held a dominant share in the market in 2021 as their manufacturing requires less source and time. Moreover, a large number of ongoing clinical trials and their encouraging results are other factors driving the segmental growth. For instance, in May 2022, Nouscom presented the promising result of phase-I trial evaluating NOUS-209, off-the shelf, and personalized viral vectored immunotherapies in combination with PD-1 checkpoint inhibitors for the treatment of solid tumors.

“Amongst neoantigen type, the synthetic long peptide category to witness higher CAGR during the forecast period”
On the basis of neoantigen type, the market is segmented into a nucleic acid, dendritic cell, tumor cell, and synthetic long peptide. The synthetic long peptide category is expected to witness higher CAGR during the forecast period owing to its cost-effectiveness and ability to overcome immune tolerance. Moreover, key players have adopted strategic alliances to design novel peptide neoantigen vaccine, which is also having a positive impact on market growth. For instance, in July 2022, Amazon partnered with Fred Hutchinson Cancer Center to initiate a clinical trial evaluating the safety of personalized neoantigen peptide vaccine in patients with melanoma or breast cancer.

“Amongst application, melanoma category to hold a significant share in the market in 2021”
On the basis of application, the market is segmented into melanoma, breast cancer, gastrointestinal, lung cancer, and others. The melanoma category held a significant share of the market in 2021 due to a surge in the incidences of melanoma. According to the American Cancer Society, approximately 97,610 new melanomas will be diagnosed in 2023. Moreover, the unmet need for targeted therapy and the rising number of ongoing clinical trials is also driving segmental growth. For instance, according to a study published in Nature Medicine, a personalized long-peptide vaccine that can target up to 20 personal neoantigens per patient has been successful in preventing melanoma in patients at high risk for recurrence.

“North America to hold a significant share in the market”
In 2021, North America held a significant share of the global neoantigen cancer vaccine market, which is due to several factors, including the presence of major key players in the region, the surge in the geriatric population and the subsequent increase in the prevalence of cancer, highly developed healthcare system, the higher adoption of technically advanced products, and favorable government policies for the launch of advanced products. For instance, in May 2022, U.S. FDA gave clearance to Nouscom for its investigational new drug (IND) candidate VAC85135, an off-the shelf, viral vector-based cancer vaccine. In addition, the rising investment by key players is also boosting the growth of the market in the region. For instance, in November 2021, Nykode Therapeutics entered into collaboration with Regenron for the development of neoantigen cancer vaccines.

Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:
The global neoantigen cancer vaccine market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

ページTOPに戻る

Table of Contents